Understand the source comparison
Follistatin-344 Benefits: Research Application Comparison
Muscle hypertrophy research Myostatin sequestration → SMAD pathway inhibition → enhanced satellite cell proliferation 14–28 days for measurable fiber diameter increase 8–15% lean mass increase over 8–12 weeks (animal models) IGF 1 LR3 or MK 677 for dual-pathwa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Muscle hypertrophy research
- Myostatin sequestration → SMAD pathway inhibition → enhanced satellite cell proliferation
- 14–28 days for measurable fiber diameter increase
- 8–15% lean mass increase over 8–12 weeks (animal models)
- IGF 1 LR3 or MK 677 for dual-pathway anabolic signaling
- Strongest evidence base; well-characterized dose-response relationship
- Metabolic health studies
- Reduced intramyocellular lipid → improved insulin sensitivity
- 21–42 days for HOMA-IR improvement
- 10–14% improvement in insulin sensitivity (human trial data)
- Tesofensine for synergistic fat oxidation and glucose uptake
- Emerging but compelling; metabolic effects secondary to lean mass increase
- Tissue repair and wound healing
- Activin inhibition → enhanced fibroblast activity and collagen synthesis
- 7–14 days for visible tissue remodeling
- 20–35% reduction in wound closure time (murine dermal models)
- BPC 157 Peptide or TB 500 Thymosin Beta 4 for complementary angiogenesis
- Limited human data; mechanism validated in cell culture and animal studies
- Sarcopenia and age-related muscle wasting
- Reversal of myostatin upregulation seen in aging populations
- 28–56 days for functional strength improvement
- 15% muscle mass increase, 30% grip strength improvement (aged murine models)
- Tesamorelin Peptide for GH-axis support in older populations
- High therapeutic potential; awaiting larger Phase III trials
- This comparison illustrates that follistatin-344 benefits are context-dependent. The peptide excels in hypertrophy research and sarcopenia models where myostatin is the limiting factor, but its effects are less pronounced in populations with already-low myostatin expression or in contexts where anabolic signaling is not the rate-limiting step.